GHK-Cu: A Research Overview of a Copper-Binding Tripeptide

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a tripeptide complex formed by the sequence glycine-histidine-lysine with a coordinated copper ion. First isolated from human plasma, GHK-Cu has been detected in saliva, urine, and various tissues, and its plasma concentration has been reported to decline with age in some studies. The peptide's high affinity for copper(II) is attributed to the imidazole nitrogen of histidine and the alpha-amino group, forming a stable complex that can participate in redox chemistry.

In preclinical research, GHK-Cu has been examined for its influence on extracellular matrix components. In vitro studies using fibroblast cultures have reported that GHK-Cu can stimulate collagen and glycosaminoglycan synthesis, and may modulate the expression of matrix metalloproteinases and their inhibitors. These effects are often described as pro-remodeling, though the precise signaling pathways remain under investigation. Proposed mechanisms include copper delivery to cells, activation of growth factor receptors, and modulation of gene expression via copper-dependent transcription factors.

Additional research has explored the peptide's antioxidant and anti-inflammatory properties. GHK-Cu has been shown to scavenge reactive oxygen species and to influence cytokine production in some cell models. Animal studies, primarily in wound-healing and skin-aging models, have reported accelerated tissue repair and improved histological outcomes, but these findings are not directly translatable to human clinical use.

GHK-Cu is not approved by regulatory agencies for any therapeutic indication. It is supplied for research-use-only purposes, and all data described here are from laboratory and animal studies. Researchers should note that reported effects are model-dependent, and rigorous controlled trials are needed to establish any clinical utility. This overview does not endorse or recommend any human application.